Neurocrine Improves Financial Position by Partnering with Abbott and Boehringer Ingelheim

By Heather Cartwright

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 13 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1369     ISSN: 1756-7874

Section: Joint Venture



Neurocrine Biosciences announced two deals in the space of 24 hours with Abbott, for its experimental drug elagolix, and with Boehringer Ingelheim, to discover and develop small molecule G-protein coupled receptor 119 (GPR 119) agonists to treat type 2 diabetes and other indications...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details